{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:24:30Z","timestamp":1790997870697,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Background: Although the safety of COVID-19 vaccines has been demonstrated in clinical trials, real-world pharmacovigilance remains essential to detect rare or unexpected adverse events following immunization (AEFI). In Mexico, the national AEFI surveillance system is in place, yet there is limited analysis of state-level data. Objective: To characterize AEFI related to five COVID-19 vaccines and identify factors associated with AEFI type and seriousness in Nuevo Le\u00f3n, Mexico. Methods: A retrospective analysis of the State of Nuevo Le\u00f3n AEFI database was conducted, including all AEFI reports between December 2020 and June 2022 (n = 2213). Data included patient sex, age, vaccine type (Pfizer\/BioNTech, AstraZeneca, Sinovac, Moderna, CanSino), number of doses (1 or \u22652), symptom categories, and AEFI seriousness. Symptoms were classified as local or systemic and grouped by organ systems. Descriptive analysis and binary multivariate logistic regression were used to examine associations between demographic and vaccine-related factors with AEFI type and severity. Odds ratios (OR) with 95% confidence intervals (CI) were estimated. Results: Most AEFI reports involved females aged 19\u201359 years and occurred after the first vaccine dose. The most frequently reported unexpected adverse events (UAEs) were mild to moderate, including injection-site reactions, headache, chills, fatigue, nausea, fever, dizziness, weakness, myalgia, and tachycardia. The Pfizer\/BioNTech vaccine was associated with higher odds of arm pain and lower odds of hemorrhagic events. Receiving \u22652 doses increased the odds of arm pain and systemic symptoms. Less than 3% of AEFIs were classified as serious. Older adults (\u226565 years) and second vaccine doses were associated with increased odds of a serious AEFI, while female sex and receiving the Pfizer\/BioNTech vaccine were associated with reduced odds. Conclusions: In Nuevo Le\u00f3n, most AEFIs related to COVID-19 vaccination were mild to moderate and resolved without complications. Serious AEFIs were uncommon, with older age and second doses associated with higher risk, and female sex and Pfizer\/BioNTech vaccination associated with lower risk. These findings provide a local perspective on vaccine safety that complements national and international evidence.<\/jats:p>","DOI":"10.3390\/idr17050108","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:07:32Z","timestamp":1756901252000},"page":"108","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sex, Age, and COVID-19 Vaccine Characteristics Associated with Adverse Events After Vaccination and Severity: A Retrospective Analysis"],"prefix":"10.3390","volume":"17","author":[{"given":"Edgar P.","family":"Rodr\u00edguez-Vidales","sequence":"first","affiliation":[{"name":"Health Services of the State of Nuevo Leon, Ministry of Health, Monterrey 64000, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-9575","authenticated-orcid":false,"given":"Jes\u00fas M.","family":"Santos-Flores","sequence":"additional","affiliation":[{"name":"General Hospital of Sabinas Hidalgo, Ministry of Health, Sabinas Hidalgo 65270, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-3682","authenticated-orcid":false,"given":"Mara I.","family":"Garza-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Health Services of the State of Nuevo Leon, Ministry of Health, Monterrey 64000, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-4193","authenticated-orcid":false,"given":"Ana M.","family":"Salinas-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Epidemiologic and Health Services Research Unit, Mexican Institute of Social Security, Monterrey 64360, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-3910","authenticated-orcid":false,"given":"Alejandra G.","family":"Mart\u00ednez-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Histology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montes de Oca-Luna","sequence":"additional","affiliation":[{"name":"Health Services of the State of Nuevo Leon, Ministry of Health, Monterrey 64000, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma R.","family":"Marroqu\u00edn-Escamilla","sequence":"additional","affiliation":[{"name":"Health Services of the State of Nuevo Leon, Ministry of Health, Monterrey 64000, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"ref_1","unstructured":"(2025, August 01). Secretar\u00eda de Salud, Gobierno de M\u00e9xico Pol\u00edtica Nacional Rectora de Vacunaci\u00f3n Contra El SARS-CoV-2 Para La Prevenci\u00f3n de La COVID-19 En M\u00e9xico. Available online: https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/597831\/Salud_PN_Vacunaci_n_COVID-19_documento_rector__08dic20.pdf."},{"key":"ref_2","unstructured":"(2025, August 06). Comisi\u00f3n Federal Para la Protecci\u00f3n Contra Riesgos Sanitarios (COFEPRIS) Vacunas COVID-19 Autorizadas En M\u00e9xico 2022. Available online: https:\/\/www.gob.mx\/cofepris\/acciones-y-programas\/vacunas-covid-19-autorizadas."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind, Randomised Controlled Trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_6","first-page":"4418","article-title":"Side Effects after COVID-19 Vaccinations among Residents of Poland","volume":"25","author":"Camerlingo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1016\/j.vaccine.2022.08.028","article-title":"Side Effects during the Week after First Dose Vaccination with Four COVID-19 Vaccines. Results of the ProVaVac Survey Study with 13,837 People in Spain","volume":"40","author":"Cuenca","year":"2022","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Camacho Moll, M.E., Salinas Mart\u00ednez, A.M., Tovar Cisneros, B., Garc\u00eda Onofre, J.I., Navarrete Floriano, G., and Berm\u00fadez de Le\u00f3n, M. (2022). Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.834744"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.vaccine.2023.03.042","article-title":"Acute Reactions after a Homologous Primary COVID-19 Vaccination Series: Analysis of Taiwan V-Watch Data","volume":"41","author":"Su","year":"2023","journal-title":"Vaccine"},{"key":"ref_10","unstructured":"World Health Organization (2019). Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification, World Health Organization."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of Background Rates of Disease in Assessment of Vaccine Safety during Mass Immunisation with Pandemic H1N1 Influenza Vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"ref_12","unstructured":"Secretar\u00eda de Salud, M\u00e9xico (2022). Manual de Procedimientos Estandarizados Para La Vigilancia Epidemiol\u00f3gica de Eventos Supuestamente Atribuibles a La Vacunaci\u00f3n o Inmunizaci\u00f3n (ESAVI), Secretar\u00eda de Salud, M\u00e9xico."},{"key":"ref_13","unstructured":"Comisi\u00f3n Federal Para La Protecci\u00f3n Contra Riesgos Sanitarios (COFEPRIS) (2021). Farmacovigilancia de Vacunas COVID-19 Autor, COFEPRIS\/Secretar\u00eda de Salud."},{"key":"ref_14","unstructured":"(2025, May 13). Manual de Eventos Supuestamente Atribuibles a La Vacunaci\u00f3n o Inmunizaci\u00f3n (ESAVI)|Centro Nacional Para La Salud de La Infancia y Adolescencia|Gobierno|Gob.Mx. Available online: https:\/\/www.gob.mx\/salud\/censia\/documentos\/manual-de-eventos-supuestamente-atribuibles-a-la-vacunacion-o-inmunizacion-esavi."},{"key":"ref_15","unstructured":"(2023, November 28). Secretar\u00eda de Salud Reporte Mensual ESAVI Por Vacuna Contra COVID19. Available online: https:\/\/www.gob.mx\/salud\/documentos\/reporte-mensual-esavi-por-vacuna-contra-covid19."},{"key":"ref_16","unstructured":"(2023, November 29). Government of Canada Reporting Adverse Events Following Immunization (AEFI) in Canada. Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/reporting-adverse-events-following-immunization\/form.html."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.11606\/s1518-8787.2021055003734","article-title":"Eventos adversos p\u00f3s-vacina\u00e7\u00e3o contra o SARS-CoV-2 (COVID-19) no estado de Minas Gerais","volume":"55","author":"Sato","year":"2021","journal-title":"Rev. Sa\u00fade P\u00fablica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijid.2022.03.007","article-title":"Adverse Events Following COVID-19 Vaccination in South Korea between February 28 and August 21, 2021: A Nationwide Observational Study","volume":"118","author":"Lee","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_19","unstructured":"CIOMS, and WHO (2012). Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS\/WHO Working Group on Vaccine Pharmacovigilance, World Health Organization."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.vaccine.2023.03.054","article-title":"Real-Life Safety Profile of mRNA Vaccines for COVID-19: An Analysis of VAERS Database","volume":"41","author":"Montanaro","year":"2023","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, G., Li, X., Sun, M., Zhou, Y., Yin, M., Zhao, B., and Li, X. (2021). COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.669010"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Guo, W., Deguise, J., Tian, Y., Huang, P.C.-E., Goru, R., Yang, Q., Peng, S., Zhang, L., Zhao, L., and Xie, J. (2022). Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.870599"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zou, C., Xue, X., and Qian, J. (2022). Characteristics and Comparison of Adverse Events of Coronavirus Disease 2019 Vaccines Reported to the United States Vaccine Adverse Event Reporting System Between 14 December 2020 and 8 October 2021. Front. Med., 9.","DOI":"10.3389\/fmed.2022.826327"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.26339","article-title":"Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System","volume":"91","author":"Frontera","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.toxrep.2021.04.003","article-title":"Safety of COVID-19 Vaccines Administered in the EU: Should We Be Concerned?","volume":"8","author":"Calina","year":"2021","journal-title":"Toxicol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mendez-Lizarraga, C.A., Chacon-Cruz, E., Carrillo-Meza, R., Hern\u00e1ndez-Mil\u00e1n, N.S., Inustroza-S\u00e1nchez, L.C., Ovalle-Marroqu\u00edn, D.F., Machado-Contreras, J.R., Ceballos Zu\u00f1iga, O., Bejarano-Ram\u00edrez, V., and Aguilar-Aguayo, C. (2022). Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico. Vaccines, 10.","DOI":"10.3390\/vaccines10081196"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against COVID-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw. Open"}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/17\/5\/108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:38:37Z","timestamp":1760035117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/17\/5\/108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["idr17050108"],"URL":"https:\/\/doi.org\/10.3390\/idr17050108","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}